Evotec SE American Depositary Shares (EVO)
Stock · NASDAQ · Health Care
$1.4as of 10/16/2026
Price chart
Active signals
EVO Signal Track Record
How signals performed across all stocks →What EVO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -4.0% | 34% | October 5, 2026 |
| Bollinger Band Breakdown | 24 | -1.1% | 38% | September 10, 2026 |
| Bollinger Band Breakout | 22 | -6.6% | 41% | August 12, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -3.8% | 43% | February 4, 2026 |
| Any 20-session window (baseline) | -3.0% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EVO
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidne…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4,461
- Website
- www.evotec.com/
Fundamentals
- 1-day range
- $1.39$1.44
- Market cap
- $693.72M
- P/E (trailing)
- —
- P/E (forward)
- -7.47
- EPS (trailing)
- $-1.11
- Dividend yield
- —
- Beta
- 1.98
- Avg. volume
- 103.5K
Forecasts
3 analyst ratings
Evotec SE American Depositary Shares Competitors
Chosen by industry and closest market cap.
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- NGNENeurogene Inc. Common Stock$23.25▼ 2.92%Market cap $680.52MP/E —$15.93$43.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| NGNE Neurogene Inc. Common Stock | $680.52M | — | $23.25 | ▼ 2.92% | $15.93$43.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $4 Price Targetbenzinga · 10/14/2026
- 4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicinesYahoo · 9/29/2026
- Evotec Announces Chief Scientific Officer TransitionYahoo · 9/29/2026
- APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINESYahoo · 9/29/2026
- Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue waveYahoo · 9/24/2026
- Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market ShareYahoo · 9/23/2026
- Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global MarketYahoo · 9/23/2026
- Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030Yahoo · 9/22/2026
- Capitalize on Compound Management Disruption: Track Brooks Life Sciences, Tecan, Hamilton and Evotec as automation transforms R&D economics and competitive ROIYahoo · 9/22/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 8.15M
- Total value held
- $20.19M
- Institutional holders
- 45
- Unknown4.60M
- Unknown1.07M
- Unknown627.3K
- Unknown509.1K
- Unknown283.6K
- Unknown259.7K
- Unknown122.3K
- Unknown119.4K
- Unknown99.6K
- Unknown87.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Evotec featured in multiple drug discovery outsourcing reports
Evotec has been highlighted in several recent industry reports focusing on AI-driven drug discovery and toxicology testing. These publications position the company alongside major peers like Charles River and WuXi AppTec as a key player in global R&D outsourcing. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions, while analyst price targets remain significantly higher than the current market price.
Evotec featured in multiple drug discovery outsourcing reports. Evotec has been highlighted in several recent industry reports focusing on AI-driven drug discovery and toxicology testing. These publications position the company alongside major peers like Charles River and WuXi AppTec as a key player in global R&D outsourcing. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions, while analyst price targets remain significantly higher than the current market price.